Abstract
Rabies is a zoonose affecting wild and domestic animals and transmitted to humans through bites or scratches, causing over 60,000 human deaths, annually. The disease results from the transmission of a neurotropic virus leading to invariably deadly encephalitis. The post-exposure prophylaxis consists of careful washing and disinfection of the wound, antibiotherapy and tetanus prophylaxis when needed. Furthermore, rabies vaccine and rabies immunoglobulin [RIG] administration should be applied according to the type of wound, and the animal involved, according to the WHO protocols that are regularly updated. Unfortunately it is sometimes difficult to obtain RIG in some countries due to their high cost, leading to suboptimal treatment and possible death. Also, observance can be weak, due to the number of repeated visits required with protocols [up to five visits over 28 days]. These limitations justify research on new vaccines which were not conclusive at the moment. New RIGs are under development, including a monoclonal antibody cocktail which is more promising in a near future. Finally, vaccination protocols are in the way of being shortened in given conditions. Further studies are needed to validate these new practices.
Keywords: Humans, post exposure prophylaxis, rabies immunoglobulin, rabies, recommendations, vaccines.
Infectious Disorders - Drug Targets
Title:Current Perspectives on Rabies Postexposure Prophylaxis
Volume: 15 Issue: 1
Author(s): Agathe Blaise and Philippe Gautret
Affiliation:
Keywords: Humans, post exposure prophylaxis, rabies immunoglobulin, rabies, recommendations, vaccines.
Abstract: Rabies is a zoonose affecting wild and domestic animals and transmitted to humans through bites or scratches, causing over 60,000 human deaths, annually. The disease results from the transmission of a neurotropic virus leading to invariably deadly encephalitis. The post-exposure prophylaxis consists of careful washing and disinfection of the wound, antibiotherapy and tetanus prophylaxis when needed. Furthermore, rabies vaccine and rabies immunoglobulin [RIG] administration should be applied according to the type of wound, and the animal involved, according to the WHO protocols that are regularly updated. Unfortunately it is sometimes difficult to obtain RIG in some countries due to their high cost, leading to suboptimal treatment and possible death. Also, observance can be weak, due to the number of repeated visits required with protocols [up to five visits over 28 days]. These limitations justify research on new vaccines which were not conclusive at the moment. New RIGs are under development, including a monoclonal antibody cocktail which is more promising in a near future. Finally, vaccination protocols are in the way of being shortened in given conditions. Further studies are needed to validate these new practices.
Export Options
About this article
Cite this article as:
Blaise Agathe and Gautret Philippe, Current Perspectives on Rabies Postexposure Prophylaxis, Infectious Disorders - Drug Targets 2015; 15 (1) . https://dx.doi.org/10.2174/1871526515666150320161630
DOI https://dx.doi.org/10.2174/1871526515666150320161630 |
Print ISSN 1871-5265 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3989 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Abeta DNA Vaccination for Alzheimers Disease: Focus on Disease Prevention
CNS & Neurological Disorders - Drug Targets Drug Targets for Rational Design against Emerging Coronaviruses
Infectious Disorders - Drug Targets Astrocytes as an HIV Reservoir: Mechanism of HIV Infection
Current HIV Research Medicinal and Therapeutic Potential of Herbs and Plant Metabolites / Extracts Countering Viral Pathogens - Current Knowledge and Future Prospects
Current Drug Metabolism The Biology of Persistent Infection: Inflammation and Demyelination Following Murine Coronavirus Infection of the Central Nervous System
Current Immunology Reviews (Discontinued) Caring for HIV-Infected Patients in the ICU in The Highly Active Antiretroviral Therapy Era
Current HIV Research Human Parvovirus B19: An Infectious Agent with the Potential to Induce and Trigger Rheumatic Disease
Current Rheumatology Reviews Brain Inflammation, Cholesterol, and Glutamate as Interconnected Participants in the Pathology of Alzheimers Disease
Current Pharmaceutical Design Porphyrin Photosensitised Processes in the Prevention and Treatment of Water- and Vector-Borne Diseases
Current Medicinal Chemistry Recent Patents in CNS Drug Discovery: The Management of Inflammation in the Central Nervous System
Recent Patents on CNS Drug Discovery (Discontinued) Regulation of Apoptosis by Gram-Positive Bacteria: Mechanistic Diversity and Consequences for Immunity
Current Immunology Reviews (Discontinued) Mortality from Herpes Simplex Virus (HSV) Infection in Australian Children, 1999-2011 Using National Datasets
Infectious Disorders - Drug Targets The Efficacy of Viral Capsid Inhibitors in Human Enterovirus Infection and Associated Diseases
Current Medicinal Chemistry Src Inhibitors and Angiogenesis
Current Pharmaceutical Design Update on ICOS: A Possible Target for Turning-Off Autoimmunity
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Regulation of Innate Immune Responses in the Central Nervous System
CNS & Neurological Disorders - Drug Targets Neurovirulence of SARS CoV2: From Clinical Data to Preclinical Neuropsychological Exploration
Coronaviruses Algae Polysaccharides’ Chemical Characterization and their Role in the Inflammatory Process
Current Medicinal Chemistry TNF-α Inhibition as a Treatment Strategy for Neurodegenerative Disorders: New Drug Candidates and Targets
Current Alzheimer Research Pathophysiogenesis of Mesial Temporal Lobe Epilepsy: Is Prevention of Damage Antiepileptogenic?
Current Medicinal Chemistry